CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy

This is an open-label phase 1 study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806 and IL13Ra2 (referred to as "CART-EGFR-IL13Ra2 cells") in patients with newly diagnosed, EGFR-amplified, MGMT-unmethylated glioblastoma, without evidence of disease recurrence/progression following completion of initial radiotherapy.

NCT Number	NCT06973096
Lead Sponsor	University of Pennsylvania Collaborators: Kite Pharma (a Gilead Company)
Conditions	Glioblastoma
Enrollment	9 participants
Start Date	2025-07-18
Primary Completion	2042-07 (estimated)
Study Completion	2042-07 (estimated)
Updated on ClinicalTrials.gov	2026-07-22